Article Text

This article has a correction. Please see:

Download PDFPDF
CD10 expression in 325 testicular germ cell tumours
  1. Christian D Fankhauser1,
  2. Tullio Sulser1,
  3. Qing Zhong2,
  4. André Barghorn2,3,
  5. Holger Moch2,
  6. Peter K Bode2
  1. 1Department of Urology, University Hospital Zurich, Zurich, Switzerland
  2. 2Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
  3. 3Medica, Institute of Pathology, Zurich, Switzerland
  1. Correspondence to Dr Peter K Bode, Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, Zurich 8091, Switzerland; peterkarl.bode{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


CD10 is a cell surface neutral endopeptidase expressed by lymphoid precursor cells, germinal centre B lymphocytes, and some myelocytes.1 Therefore, it is used as marker for the categorisation of acute leukaemia and subclassification of lymphomas.2 With focus on germ cell tumours Del Sordo et al3 reported in a cohort of 135 germ cell tumours expression of 92% for seminomas, whereas non-seminomatous germ cell tumours were negative. The authors concluded that CD10 serves to differentiate seminoma from non-seminomatous germ cell tumours. The aim of this study was to describe CD10 expression in the so far largest germ cell tumour set and to validate the findings of previous studies.

Materials and methods

Tissue microarray

The tissue microarray used for this study has previously been described.4 It includes 325 testicular germ cell tumours: 207 classic seminomas, 4 spermatocytic seminomas, 19 pure embryonal carcinomas, 1 pure mature teratoma and 94 mixed germ cell tumours. In mixed germ cell tumours each component was separately punched and represented on the tissue microarray. Finally, 442 different histologic tumour components were considered for evaluation.


CD10 was detected using the prediluted antibody from Ventana (790–4506). The staining was performed with the Ventana Benchmark automated staining system (Ventana Medical Systems, Tucson, AZ). Samples were dichotomised into positive versus negative. The intensity of immunostaining was graded as absent, weak, moderate and strong. The threshold for …

View Full Text


  • Contributors Author contributions: PKB had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: CDF, TS, QZ, AB, HM, PKB. Acquisition of data: CDF, PKB. Analysis and interpretation of data: CDF, PKB. Drafting of the manuscript: CDF, TS, QZ, AB, HM, PKB. Critical revision of the manuscript for important intellectual content: CDF, TS, QZ, AB, HM, PKB. Supervision: PKB.

  • Competing interests None.

  • Ethics approval Cantonal ethics committee Zurich.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles

  • Errata
    BMJ Publishing Group Ltd and Association of Clinical Pathologists